title: Electrolyte abnormalities due to irinotecan administration in metastatic HER-2 positive breast  cancer patients.
authors: I
authors: I
authors: Petekkaya
authors: T
authors: T
authors: Akin
authors: G
authors: G
authors: Gezgen
authors: E C
authors: EC
authors: Roach
authors: Y
authors: Y
authors: Ozisik
authors: K
authors: K
authors: Altundag
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D006996:Hypocalcemia / Q000139:chemically induced*; D007008:Hypokalemia / Q000139:chemically induced*; D000077146:Irinotecan; D008875:Middle Aged; D009362:Neoplasm Metastasis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D002166:Camptothecin; D000077146:Irinotecan; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human